Name | Abingdon Health |
---|---|
Epic | ABDX |
Isin | GB00BLF79J41 |
Industry | Medical Equipment and Services |
Latest share price | 8.00p | Net gearing | n/a |
---|---|---|---|
Market capitalisation | £15.49 | Debt ratio | n/a |
Shares in issue | 193.63 | Debt-to-equity ratio | n/a |
P/E ratio | n/a | Assets / equity ratio | n/a |
Total dividends per share | n/a | Price to book value | n/a |
Dividend yield | n/a | ROCE | -48.11 |
Dividend cover | n/a | EPS growth | n/a |
Earning per share | -0.42 | 52-week high / low | 6.75p / 11.50p |
Type | Ex-date | Pay-date | Net-dividend |
---|---|---|---|
No dividends declared |
Company name | Abingdon Health |
---|---|
Address | York Biotech Campus, Sand Hutton, York, England, United Kingdom, YO41 1LZ |
Telephone | +44 (0)1904 406082 |
Website | http://www.abingdonhealth.com/ |
Director | Position |
---|---|
Mr Chris Henry Francis Yates | CEO |
Dr Christopher Hand | Non-Executive Chairman |
Ms Mary G Tavener | Independent Non-Executive Director |
Assets £ (m) | 2024 | 2023 | 2022 |
---|---|---|---|
Reporting date | 30/06/24 | 30/06/23 | 30/06/22 |
Intangible asssets and goodwill | 0.53 | 0.09 | 0.04 |
Investments and other non-current assets | 0.01 | n/a | n/a |
Total non-current assets | 1.54 | 1.35 | 1.81 |
Inventory / work in progress | 0.44 | 0.33 | 0.53 |
Trade and other receivables | 1.47 | 1.15 | 8.03 |
Cash and equivalents | 1.44 | 3.24 | 2.4 |
Other current assets and asset held for resale | 0.2 | 0.05 | n/a |
Total of all assets | 5.09 | 6.11 | 12.77 |
Liabilities £ (m) | 2024 | 2023 | 2022 |
---|---|---|---|
Short term liabilities | 1.82 | 2.12 | 5.32 |
Long term liabilities | 1.02 | 1.02 | 1.01 |
Other liabilites / pension etc | n/a | n/a | n/a |
Total of all liabilities | 2.84 | 3.14 | 6.34 |
Net assets £ (m) | 2024 | 2023 | 2022 |
---|---|---|---|
Net assets | 2.25 | 2.97 | 6.43 |
Equity £ (m) | 2024 | 2023 | 2022 |
---|---|---|---|
Share capital | 0.08 | 0.08 | 0.08 |
Minority interests | n/a | n/a | n/a |
Retained earnings | -28.76 | -27.49 | -24.11 |
Share premium account | 30.81 | 30.31 | 30.31 |
Total equity | 2.25 | 2.97 | 6.43 |
Income £ (m) | 2024 | 2023 | 2022 |
---|---|---|---|
Turnover | n/a | n/a | n/a |
Operating profit | -1.37 | -3.59 | -21.53 |
Pre-tax profit | -1.4 | -3.57 | -21.59 |